What's breaking now, across thousands of outlets.
Nvidia-backed Iambic Therapeutics will begin trading Thursday after pricing its $150 million initial public offering Wednesday night. The cancer-focused biotech sold 9.38 million shares {$IAM} at $16 apiece. The float adds ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
ChatGPT is a good tool for drafting parts of a discovery phase: a problem statement, a first list of requirements, a summary of a call.
For card issuers, artificial intelligence is moving closer to the transaction itself. Eighty-nine percent of issuers plan to adopt or expand at least one AI fraud capability, according to the PYMNTS…
A repo called REA — "Reverse Engineer Anything" picked up about 183,000 stars in a single week and went to #1 on GitHub's weekly trending page.
Watch more: Digital Shift with Payroc’s Paul Vienneau The most important question for software companies building payments used to be whether they had the engineers, budget and time to do it…
Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate…
Supply constraints might not be what's holding back companies from buying more AI chips.
